The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / C••••••• P••••••••• L•••••• C•••••

A•••••• Investment Partners Acquires C••••••• P••••••••• L••••••

Platform acquisitionclosedannounced Jun 6, 2024closed Jun 6, 2024Fact
What happened
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
healthcare / pharma
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
3 named
Buy side
  • J•• T••••Deal partnerconfirmed
    J•• T••••, Principal at A••••••, added, “CPL represents A••••••’s thirteenth investment in the life sciences, personal care and nutrition segments.
  • A•••••• Investment Partners (“A••••••”), a private investment firm, is pleased to announce that one of its affiliates has closed its acquisition of C••••••• P••••••••• L•••••• C••••• (“CPL” or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-
Side not stated
  • A•••••• Investment Partners (“A••••••”), a private investment firm, is pleased to announce that one of its affiliates has closed its acquisition of C••••••• P••••••••• L•••••• C••••• (“CPL” or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-
Evidence
A•••••• Investment Partners (“A••••••”), a private investment firm, is pleased to announce that one of its affiliates has closed its acquisition of C••••••• P••••••••• L•••••• C••••• (“CPL” or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.
A•••••• Investment Partners Acquires C••••••• P••••••••• L•••••• | Private Equity Intelligence | DFX